Sharma R P, Smillie J, Laverty R
J Pharm Pharmacol. 1984 Jul;36(7):441-5. doi: 10.1111/j.2042-7158.1984.tb04421.x.
The tissue and subcellular pharmacokinetics of gold following single and repeated oral doses of triethylphosphine gold (auranofin) has been studied in rats. After a single dose, the tissue and subcellular gold levels were 5-10 times lower than those reached with injectable gold compounds. In the liver tissues, gold concentrations peaked within 24 h followed by a biphasic clearance, with an initial rapid phase (t1/2 32 h) and a slow terminal phase (t 1/2 11 days). Renal gold concentrations continued to increase for 3 to 5 days and then decreased exponentially with a first order t 1/2 of about 7 days. Intracellularly, between 60-80% of hepatic and 50-70% of renal gold was present in the cytosol. In rats given repeated doses of auranofin, the hepatic and renal gold concentrations were 3-5 times higher than those measured after a single dose. The proportion of cellular gold present in the cytosol was markedly lower, with 43% in the liver and 30% in kidney tissues. In both the liver and kidney, gold concentrations were dose-dependent, whereas in the gastrointestinal tissues the increases as a function of dose were minimal.
在大鼠中研究了单次和重复口服三乙膦金(金诺芬)后金的组织和亚细胞药代动力学。单次给药后,组织和亚细胞中的金水平比注射用金化合物达到的水平低5至10倍。在肝组织中,金浓度在24小时内达到峰值,随后呈双相清除,有一个初始快速相(t1/2 32小时)和一个缓慢的终末相(t1/2 11天)。肾金浓度持续增加3至5天,然后以约7天的一级t1/2呈指数下降。在细胞内,肝中60 - 80%的金和肾中50 - 70%的金存在于胞质溶胶中。在给予重复剂量金诺芬的大鼠中,肝和肾中的金浓度比单次给药后测得的浓度高3至5倍。胞质溶胶中细胞金的比例明显较低,肝组织中为43%,肾组织中为30%。在肝和肾中,金浓度均呈剂量依赖性,而在胃肠道组织中,作为剂量函数的增加最小。